We are pleased to launch two new reports:
our new patient experience report "Living for a rare or less common cancer, patient experiences of treatment and care" - what does the evidence from the National Cancer Patient Experience Survey show us about experience of people with a rare or less common cancer? What is it that can make the difference to that experience?
Speaking up for patients "Patient organisation involvement in Health Technology Assessment (HTA) with a focus on Patient and Clinical Engagement (PACE) at the Scottish Medicines Consortium (SMC)" on patient group involvement in the new Patient and Clinical Engagement (PACE) process at the Scottish Medicines Consortium (SMC) - what can we learn from these experiences and what can we share?